Levofloxacin preventive treatment for household contacts of drug-resistant tuberculosis was modelled in 189 countries, with age-dependent risks of progression, death and side effects. Extending treatment from under-15s to age 45 was cost-effective in 160 countries, at a cost per healthy year gained below 30% of income per head. Treating contacts of all ages would avert 9,960 deaths globally, but result in 71,000 serious side effects.
Why it is interesting: Treating without a test for infection averted more and cost less than testing contacts first.
Abstract — the authors' own words, CC BY
Background
Tuberculosis preventive treatment (TPT) with levofloxacin reduces tuberculosis disease incidence in multidrug-resistant or rifampicin-resistant (MDR/RR)-tuberculosis household contacts. However, with age, disease progression risk falls and the frequency of adverse events (AE) rises. Methods
To inform decision-makers, we evaluated the cost-effectiveness of expanding the use of MDR/RR-TPT by age, with and without tests of tuberculosis infection. We modelled MDR/RR-household contact management (HHCM) in 189 countries, incorporating age-dependent risks of disease progression, death and AEs. Incremental cost-effectiveness ratios were calculated as USD/disability-adjusted life year (DALY) averted, and as a fraction of per capita gross domestic product (GDP). Findings
Compared to baseline of MDR/RR-HHCM with TPT for those Interpretation
Expanding MDR/RR-TPT use to older ages without testing appears cost-effective in most settings, but may require substantial resources and result in large numbers of AEs. Funding
Unitaid
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.